Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study

Blood (2019) 134 (Supplement_1): 692.

https://doi.org/10.1182/blood-2019-123143

Published: 2019

Journal Articles

Darbepoetin Alfa for the Treatment of Anemic Patients with Myelodysplastic Syndrome: A Belgian Single-Arm, Companion Trial to the Arcade Phase 3 Study

Michel Delforge, Dominiek Mazure, Isabelle Vande Broek, Jo Caers, Sejal Badre, Bhakti Mehta, Cisio De Oliveira Brandao

Blood (2017) 130 (Supplement 1): 5318.

https://doi.org/10.1182/blood.V130.Suppl_1.5318.5318

Published: 2017

Journal Articles

General Adaptive Functioning in Survivors of Childhood Acute Lymphoblastic Leukemia

Julie N Baran, MS, Robert B Noll, PhD, Lisa M Jacola, PhD, Victoria W Willard, PhD, Kristina K Hardy, PhD, Leanne Embry, PhD, John A Kairalla, PhD, Nikita Saoji, MPH, Stephanie E Hullmann, PhD, Naomi Winick, MD

Blood (2016) 128 (22): 4770.

https://doi.org/10.1182/blood.V128.22.4770.4770

Published: 2016

Journal Articles

Structural Features of ROR1 Required for Complexing with ROR2 and Enhancing Chemokine-Induced Migration and Leukemia-Cell Proliferation, Which Can be Blocked By the Anti-ROR1 Mab Cirmtuzumab (UC-961)

Jian Yu, PhD, Liguang Chen, MD PhD, George F. Widhopf, II, PhD, Suping Zhang, PhD, Bing Cui, PhD, Rongrong Wu, PhD, Ling Zhang, PhD, Thomas J. Kipps, MD, PhD

Blood (2015) 126 (23): 1741.

https://doi.org/10.1182/blood.V126.23.1741.1741

Published: 2015

Journal Articles

Mobilization Of Blasts and Leukemia Stem Cells by Anti-CXCR4 Antibody BMS-936564 (MDX 1338) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Sylvia Chien, Lauren E. Beyerle, Brent L. Wood, MD, PhD, Elihu H. Estey, MD, Frederick R. Appelbaum, MD, Pina M. Cardarelli, Ph.D., Peter Sabbatini, PhD, Suresh Shelat, MD-PhD, Lewis Cohen, MD, MS, Pamela S. Becker, MD, PhD

Blood (2013) 122 (21): 3882.

https://doi.org/10.1182/blood.V122.21.3882.3882

Published: 2013

Journal Articles

CD34-Selected, T Cell-Depleted Alternative Donor Stem Cell Transplantation For Children

Andrew Gilman, Michael Eckrich, MD, Stacy Epstein, PharmD, Carrie Barnhart, RN, Javier Oesterheld, MD, Darci Grochowski, PA, Tracy Fukes, RN, Maria Lacaria, RN, Mark Cannon, BA

Blood (2013) 122 (21): 2064.

https://doi.org/10.1182/blood.V122.21.2064.2064

Published: 2013

Journal Articles

Treatment Patterns & Survival In Multiple Myeloma Patients Sequentially Exposed To Thalidomide, Bortezomib & Lenalidomide In a UK Single Centre

Julie L Tarant, MBChB MRCP(UK), John Ashcroft, MD, MBBChir, PhD, MRCP, MA, FRCPath, Sylvia Feyler, MD PhD, Roger G Owen, MD, Christopher Parrish, MA, MB, BChir, MRCP, Gordon Cook, MD, PhD

Blood (2013) 122 (21): 5380.

https://doi.org/10.1182/blood.V122.21.5380.5380

Published: 2013

Journal Articles

Pomalidomide in Combination with Low-Dose Dexamethasone: Demonstrates a Significant Progression Free Survival and Overall Survival Advantage, in Relapsed/Refractory MM: A Phase 3, Multicenter, Randomized, Open-Label Study

Meletios A. Dimopoulos, MD, Martha Q Lacy, MD, Philippe Moreau, MD, Katja C Weisel, MD, Kevin W. Song, MD, FRCPC, Michel Delforge, MD, PhD, Lionel Karlin, MD, Hartmut Goldschmidt, MD, Anne Banos, MD, Albert Oriol, MD, Xin Yu, PhD, Lars Sternas, MD, Christian J. Jacques, MD, Mohamed Zaki, MD, Jesús F San Miguel, MD, PhD

Blood (2012) 120 (21): LBA-6.

https://doi.org/10.1182/blood.V120.21.LBA-6.LBA-6

Published: 2012

Journal Articles

MicroRNA Profiling in Patients with CLL B Cells Expressing the Unmutated IGHV1-69 Gene

Laura Z. Rassenti, Ph.D., Emanuela M. Ghia, PhD, Lillian Werner, Donna Neuberg, ScD, Muller Fabbri, MD, Stefano Volinia, PhD, George F. Widhopf, II, PhD, Carlo M. Croce, MD, Thomas J. Kipps, M.D., Ph.D

Blood (2011) 118 (21): 2846.

https://doi.org/10.1182/blood.V118.21.2846.2846

Published: 2011

Journal Articles

Bone Marrow (BM) Minimal Residual Disease (MRD) at End of Induction and Interim Maintenance Is Highly Predictive of Outcome in Children with Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Treated on the Children’s Oncology Group Study 1991

Yousif Matloub, MD, Paul S. Gaynon, MD, Somasundaram Jayabose, MD, Bruce C. Bostrom, MD, Stephen P. Hunger, MD, Anne L Angiolillo, MD, Meenakshi Devidas, PhD, Stephen Linda, William L. Carroll, MD, Naomi Winick, MD, Harland Sather, PhD, Sharon R Pine, PhD

Blood (2008) 112 (11): 701.

https://doi.org/10.1182/blood.V112.11.701.701

Published: 2008

Journal Articles

Delayed Response to Lenalidomide in International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS).

Erev E. Tubb, MD, Emmanuel C. Besa, MD, Aristoteles Giagounidis, MD, Gustavo A. Fonseca, MD

Blood (2007) 110 (11): 1447.

https://doi.org/10.1182/blood.V110.11.1447.1447

Published: 2007

Journal Articles

Dendritic Cell Reconstitution Following Autologous Stem Cell Transplant with GM-CSF Support for Multiple Myeloma.

Annette J. Schlueter, MD, PhD, Judith K. Glasgow, BS, Werner Wilke, MD, PhD, Jacquie R. Marietta, MS, Raymond J. Hohl, MD, PhD, Thomas H. Carter, MD, PhD, Roger D. Gingrich, MD, PhD, Margarida D. Magalhaes-Silverman, MD

Blood (2007) 110 (11): 951.

https://doi.org/10.1182/blood.V110.11.951.951

Published: 2007

Journal Articles

Phase I Study of the [Cu, Zn] Superoxide Dismutase (SOD1) Inhibitor ATN-224 (Bis-Choline Tetrathiomolybdate) in Patients (pts) with Advanced Hematologic Malignancies.

James R. Berenson, MD, Ralph Vincent Boccia, MD, Asad Bashey, MD PhD, Alexandra M. Levine, MD, Omer N. Koc, MD, Jennifer A. Callahan, Andrew P. Mazar, PhD, Steven D. Reich, MD

Blood (2006) 108 (11): 2593.

https://doi.org/10.1182/blood.V108.11.2593.2593

Published: 2006

Journal Articles

Phase III Study of Denileukin Diftitox (ONTAK®) To Evaluate Efficacy and Safety in CD25+ and CD25- Cutaneous T-Cell Lymphoma (CTCL) Patients.

Andres Negro-Vilar, MD, PhD, Zofia Dziewanowska, MD, Eric Groves, MD, PhD, Elyane Lombardy, MD, Victor Stevens, PhD

Blood (2006) 108 (11): 696.

https://doi.org/10.1182/blood.V108.11.696.696

Published: 2006

Journal Articles

Dendritic Cell Reconstitution Following Autologous Stem Cell Transplant for Multiple Myeloma.

Annette J. Schlueter, MD, PhD, Judith K. Glasgow, BS, Werner W. Wilke, MD, PhD, Jacquie R. Marietta, BS, Raymond J. Hohl, MD, PhD, Thomas H. Carter, MD, PhD, Roger D. Gingrich, MD, PhD, Margarida D. Magalhaes-Silverman, MD

Blood (2005) 106 (11): 5212.

https://doi.org/10.1182/blood.V106.11.5212.5212

Published: 2005

Journal Articles

Microarray Analyses in a Case-Control Cohort of T-ALL Samples Identifies Gene Signature of Potential Prognostic Significance.

Stuart S. Winter, MD, Hadya Khawaja, Zeyu Jiang, PhD, Charles Kooperberg, PhD, Adolfo Ferrando, MD, Thomas Look, MD, Richard S. Larson, MD, PhD

Blood (2005) 106 (11): 1448.

https://doi.org/10.1182/blood.V106.11.1448.1448

Published: 2005

Journal Articles

Maintenance Therapy with Thalidomide/Prednisone Post Autologous Stem-Cell Transplant for Patients with Multiple Myeloma Elevates D-Dimer and Possibly Factor VIII Levels.

Michael J. Kovacs, MD, FRCPC, Judy-Anne W. Chapman, PhD, Lois Shepherd, MD, FRCPC, Ralph Meyer, MD, FRCPC, Michael Keeney, ART, FIMLS, Karen MacKinnon, MLT, Keith Stewart, MD, FRCPC, Nancy Paul, PhD, The NCIC CTG Investigators on MY.10.

Blood (2005) 106 (11): 2561.

https://doi.org/10.1182/blood.V106.11.2561.2561

Published: 2005

Journal Articles

Bortezomib Demonstrates Superior Efficacy to High-Dose Dexamethasone in Relapsed Multiple Myeloma: Final Report of the APEX Study.

Paul Richardson, P. Sonneveld, M. Schuster, D. Irwin, E. Stadtmauer, T. Facon, J. Harousseau, D. Ben-Yehuda, S. Lonial, H. Goldschmidt, D. Reece, J. San Miguel, J. Blade, M. Boccadoro, J. Cavenagh, W. Dalton, A. Boral, D. Schenkein, K. Anderson

Blood (2004) 104 (11): 1479.

https://doi.org/10.1182/blood.V104.11.1479.1479

Published: 2004

Journal Articles

Prospective Karyotype Analysis in Adult Acute Lymphoblastic Leukemia: The Cancer and Leukemia Group B Experience

Meir Wetzler, Richard K. Dodge, Krzysztof Mrózek, Andrew J. Carroll, Ramana Tantravahi, AnneMarie W. Block, Mark J. Pettenati, Michelle M. Le Beau, Stanley R. Frankel, Carleton C. Stewart, Ted P. Szatrowski, Charles A. Schiffer, Richard A. Larson, Clara D. Bloomfield

Blood (1999) 93 (11): 3983–3993.

https://doi.org/10.1182/blood.V93.11.3983

Published: 1999

NARROW

Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study

Darbepoetin Alfa for the Treatment of Anemic Patients with Myelodysplastic Syndrome: A Belgian Single-Arm, Companion Trial to the Arcade Phase 3 Study

General Adaptive Functioning in Survivors of Childhood Acute Lymphoblastic Leukemia

Structural Features of ROR1 Required for Complexing with ROR2 and Enhancing Chemokine-Induced Migration and Leukemia-Cell Proliferation, Which Can be Blocked By the Anti-ROR1 Mab Cirmtuzumab (UC-961)

Mobilization Of Blasts and Leukemia Stem Cells by Anti-CXCR4 Antibody BMS-936564 (MDX 1338) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

CD34-Selected, T Cell-Depleted Alternative Donor Stem Cell Transplantation For Children

Treatment Patterns & Survival In Multiple Myeloma Patients Sequentially Exposed To Thalidomide, Bortezomib & Lenalidomide In a UK Single Centre

Pomalidomide in Combination with Low-Dose Dexamethasone: Demonstrates a Significant Progression Free Survival and Overall Survival Advantage, in Relapsed/Refractory MM: A Phase 3, Multicenter, Randomized, Open-Label Study

MicroRNA Profiling in Patients with CLL B Cells Expressing the Unmutated IGHV1-69 Gene

Bone Marrow (BM) Minimal Residual Disease (MRD) at End of Induction and Interim Maintenance Is Highly Predictive of Outcome in Children with Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Treated on the Children’s Oncology Group Study 1991

Delayed Response to Lenalidomide in International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS).

Dendritic Cell Reconstitution Following Autologous Stem Cell Transplant with GM-CSF Support for Multiple Myeloma.

Phase I Study of the [Cu, Zn] Superoxide Dismutase (SOD1) Inhibitor ATN-224 (Bis-Choline Tetrathiomolybdate) in Patients (pts) with Advanced Hematologic Malignancies.

Phase III Study of Denileukin Diftitox (ONTAK®) To Evaluate Efficacy and Safety in CD25+ and CD25- Cutaneous T-Cell Lymphoma (CTCL) Patients.

Dendritic Cell Reconstitution Following Autologous Stem Cell Transplant for Multiple Myeloma.

Microarray Analyses in a Case-Control Cohort of T-ALL Samples Identifies Gene Signature of Potential Prognostic Significance.

Maintenance Therapy with Thalidomide/Prednisone Post Autologous Stem-Cell Transplant for Patients with Multiple Myeloma Elevates D-Dimer and Possibly Factor VIII Levels.

Bortezomib Demonstrates Superior Efficacy to High-Dose Dexamethasone in Relapsed Multiple Myeloma: Final Report of the APEX Study.

Prospective Karyotype Analysis in Adult Acute Lymphoblastic Leukemia: The Cancer and Leukemia Group B Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only